HCW Biologics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HCWB research report →
Price Chart
About the company
HCW Biologics Inc. operates as a preclinical-stage biopharmaceutical firm, primarily engaged in the discovery and advancement of novel immunotherapies. Its research and development efforts are focused on addressing chronic, low-grade inflammation and a spectrum of age-related diseases.
- CEO
- Hing C. Wong
- IPO
- 2021
- Employees
- 35
- HQ
- Miramar, FL, US
Get TickerSpark's AI analysis on HCWB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $545.80K
- P/E
- -0.03
- PEG
- 0.00
- P/S
- 0.08
- P/B
- 0.07
- EV/EBITDA
- -1.49
- Div Yield
- 0.00%
- Gross Margin
- 95.91%
- Op Margin
- -91.57%
- Net Margin
- -73.22%
- ROE
- -142.16%
- ROIC
- -39.28%
Latest fiscal year · YoY change
- Revenue
- $54.23K-97.9%
- Gross Profit
- $10.85K-98.9%
- Op Income
- $-11,257,288
- Net Income
- $-7,959,709+73.5%
- EPS
- $-63.78-1280.5%
- OCF Growth
- +5.9%
- FCF Growth
- +7.6%
- 52W High
- $29.28
- 52W Low
- $1.50
- 50D MA
- $2.55
- 200D MA
- $4.74
- Beta
- 2.42
- RSI (14)
- 31
- Avg Volume
- 381.19K
No earnings-call transcripts are available for HCWB yet.
- Free Float
- 85.8%
- Shares Outstanding
- 347.64K
- Float Shares
- 298.16K
of shares held by institutions
14 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 15.43K | 0 |
| Hrt Financial LP | 13.58K | ▼ 252.81K |
| Vanguard Fiduciary Trust Co | 6.51K | ▲ 4.61K |
| Vanguard Capital Management LLC | 2.00K | ▼ 10.02K |
| Golden State Wealth Management, LLC | 1.67K | ▼ 8.33K |
Held by 6 ETFs
Biggest fund positions in HCWB by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 29, 26 | Wong Hing C | buy | 23,210 |
| Jul 29, 26 | Flowers Lee | buy | 7,736 |
| Jul 29, 26 | GARRETT SCOTT T | buy | 7,736 |
| May 22, 26 | Wong Hing C | buy | 113,879 |
| May 22, 26 | Wong Hing C | buy | 113,879 |
| May 22, 26 | GARRETT SCOTT T | buy | 177,936 |
| May 22, 26 | GARRETT SCOTT T | buy | 177,936 |
| May 22, 26 | Byam Rebecca | buy | 14,235 |
| May 22, 26 | Byam Rebecca | buy | 14,235 |
| May 16, 25 | Wong Hing C | buy | 8,054 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our HCWB coverage
Recent articles, reports, and earnings notes.
No research on HCWB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HCWB report →HCW Biologics Announces Pricing of $1.5 Million Private Placement
globenewswire.com · Sep 24
HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells
globenewswire.com · Sep 8
HCW Biologics Strengthens U.S. Patent Estate for Its Lead Clinical-Stage Immunotherapeutic HCW9302 as Alopecia Areata Treatment
globenewswire.com · Sep 2
HCW Biologics' TGF-β Trap and IL-15 Fusion is a Novel Moiety to Enhance Immunotherapeutic Activity against Diseased Cells
globenewswire.com · Aug 25
HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results
globenewswire.com · Aug 14
HCW Biologics Inc. Announces Pricing of $1.6 Million Private Placement Offering
globenewswire.com · Jul 29
HCW Biologics Reaches Milestones for Its Proprietary Tetravalent Second-Generation T-Cell Engager Program On Track To Initiate Clinical Trials in First Half 2027
globenewswire.com · Jul 23
HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter
globenewswire.com · Jun 30
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.